Effects of growth hormone (GH) replacement therapy in GH deficient adult childhood cancer survivors on organ size and microvascularisation of kidney and skin.

Effects of growth hormone (GH) replacement therapy in GH deficient adult childhood cancer survivors on organ size and microvascularisation of kidney and skin. - Effects of GH replacement therapy on organ size and microvascularisation.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33094

Enrollment

Registered

2009-12-15

Start date

2009-10-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

growth hormone deficiency

Interventions

1 year of growth hormone substitution therapy.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: childhood cancer survivors who have been treated with cranial irradiation growth hormone deficient age > 18 years > 5 years off tumor treatment

Exclusion criteria

Exclusion criteria: growth hormone replacement therapy in the last 12 months current treatment for second malignancy severe mental disorder/dementia/inability of legal consent drug abuse/dependence for women: pregnancy

Design outcomes

Primary

Measure	Time frame
1. Change in visceral organ size, especially kidney size. 2. Change in GFR and ERPF. 3. Change in capillary density of the skin.	—

Secondary

Measure	Time frame
Change in quality of life.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)